SCHEMBL10073863

SCHEMBL10073863

COc1ccc2c(C(=O)c3ccccc3)n[nH]c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.50
FLT3 P36888 2/20 0.50
TSHR P16473 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
MEN1 O00255 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
CDK2 P24941 1/20 0.50
PRKAG1 P54619 3/20 0.49
PRKAA1 Q13131 3/20 0.49
PRKAB1 Q9Y478 3/20 0.49
ALDH1A1 P00352 4/20 0.49
HTT P42858 3/20 0.49
HPGD P15428 2/20 0.49
LMNA P02545 2/20 0.49
CYP2C19 P33261 2/20 0.49
PGR P06401 1/20 0.49
CYP2D6 P10635 1/20 0.49
SLC6A2 P23975 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073867 0.85 SMN1; SMN2 (0.45) FLT3HDAC6CDK2PRKAG1PRKAA1
SCHEMBL176882 0.84 PRKAG1 (0.66) FLT3CDK2PRKAG1PRKAA1PRKAB1
SCHEMBL13931749 0.83 TUBB1 (0.61) RAB9ANPC1L3MBTL1CASP3SENP8
SCHEMBL14001681 0.83 TUBB1 (0.52) FLT3CDK2PRKAG1PRKAA1PRKAB1
SCHEMBL4482588 0.83 FLT3 (0.65) FLT3CDK2ALDH1A1HRH1RAB9A
SCHEMBL18554248 0.81 BCHE (0.56) FLT3CYP3A4HDAC6CDK2PRKAG1
SCHEMBL10073860 0.81 PRKAG1 (0.44) FLT3KMT2AHDAC6CDK2PRKAG1
SCHEMBL17782665 0.81 FLT3 (0.47) FLT3TSHRKMT2AMEN1CDK2
SCHEMBL14387460 0.80 TUBB1 (0.49) FLT3CDK2PRKAG1PRKAA1PRKAB1
SCHEMBL13794487 0.80 L3MBTL1 (0.47) FLT3KMT2AMEN1HDAC6CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562909-B1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK SHARP & DOHME (US) 2012-06-27 EP disclosed
US-7563816-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-07-21 US disclosed
US-7563816-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-07-21 US disclosed
US-7547720-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-06-16 US disclosed
US-7547720-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-06-16 US disclosed
US-7528163-B2 N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye MERCK & CO. INC. (US) 2009-05-05 US disclosed
US-7528163-B2 N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye MERCK & CO. INC. (US) 2009-05-05 US disclosed
EP-1663987-B1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2009-03-18 EP disclosed
US-7410992-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-12 US disclosed
US-7410992-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-12 US disclosed
US-20080032951-A1 Ophthalmic Compositions For Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2008-02-07 US disclosed
US-20080032951-A1 Ophthalmic Compositions For Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2008-02-07 US disclosed
US-20070129418-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-06-07 US disclosed
US-20070129418-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-06-07 US disclosed
US-7196082-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2007-03-27 US disclosed
US-7196082-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2007-03-27 US disclosed
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-01-11 US disclosed
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME LLC 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010491-A1 Ophthalmic compositions for treating ocular hypertension REN, KCNH2, KCNH3 CYP1A2 2787/4885FLT3 4764/4885TSHR 1299/4885
US-20080032951-A1 Ophthalmic Compositions For Treating Ocular Hypertension KCNH2, KCNN1, KCNH3 CYP1A2 2584/4885FLT3 4646/4885TSHR 3591/4885
US-20070129418-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNJ11, KCNN1 CYP1A2 2713/4885FLT3 4484/4885TSHR 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.